Immediately withhold tepotinib in patients with suspected interstitial lung disease/pneumonitis. Permanently discontinue tepotinib in patients diagnosed with interstitial lung disease/pneumonitis of any severity.
- TRADE NAME: Tepmetko (Merck Serono)
- INDICATIONS: Non-small cell lung cancer harboring mesenchymalepithelial transition exon 14 (METex14) skipping alterations.
- CLASS: Kinase inhibitor, MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor
- HALF-LIFE: 32 hours
- FDA APPROVAL DATE: 02/03/2021
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
CYP3A inducers, CYP3A inhibitors, P-gp inhibitors - PREGNANCY: Can cause fetal harm. Advise patient of potential risk to a fetus and the use of effective contraception.
- See adverse reactions attributed to class:
MET (mesenchymal-epithelial transition) inhibitor / MET tyrosine kinase inhibitor
Please login to view the rest of this drug profile.
Page last updated 04/06/2024
